DK2310042T3 - Anvendelse af pasireotid til behandling af endogen hyperinsulinæmisk hypoglykæmi - Google Patents

Anvendelse af pasireotid til behandling af endogen hyperinsulinæmisk hypoglykæmi

Info

Publication number
DK2310042T3
DK2310042T3 DK09793940.9T DK09793940T DK2310042T3 DK 2310042 T3 DK2310042 T3 DK 2310042T3 DK 09793940 T DK09793940 T DK 09793940T DK 2310042 T3 DK2310042 T3 DK 2310042T3
Authority
DK
Denmark
Prior art keywords
pasireotide
treatment
hypoglycaemia
endogenous
endogenous hyperinsulinemic
Prior art date
Application number
DK09793940.9T
Other languages
English (en)
Inventor
Herbert Schmid
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK2310042T3 publication Critical patent/DK2310042T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK09793940.9T 2008-07-08 2009-07-07 Anvendelse af pasireotid til behandling af endogen hyperinsulinæmisk hypoglykæmi DK2310042T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08159918 2008-07-08
PCT/EP2009/058573 WO2010003939A1 (en) 2008-07-08 2009-07-07 Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia

Publications (1)

Publication Number Publication Date
DK2310042T3 true DK2310042T3 (da) 2013-03-04

Family

ID=39876604

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09793940.9T DK2310042T3 (da) 2008-07-08 2009-07-07 Anvendelse af pasireotid til behandling af endogen hyperinsulinæmisk hypoglykæmi

Country Status (12)

Country Link
US (2) US9314508B2 (da)
EP (1) EP2310042B1 (da)
JP (1) JP5721624B2 (da)
CY (1) CY1113726T1 (da)
DK (1) DK2310042T3 (da)
ES (1) ES2399651T3 (da)
HR (1) HRP20130145T1 (da)
PL (1) PL2310042T3 (da)
PT (1) PT2310042E (da)
SI (1) SI2310042T1 (da)
SM (1) SMT201300030B (da)
WO (1) WO2010003939A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050285A1 (es) * 2003-06-24 2005-06-09 Novartis Ag Composicion farmaceutica que comprende analogos ciclicos de somatostatina
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
KR101245022B1 (ko) 2005-01-21 2013-03-19 카무러스 에이비 약제학적 지질 조성물
EP4049673A1 (en) 2007-01-08 2022-08-31 The Trustees of the University of Pennsylvania Glp-1 receptor antagonist for use in the treatment of post-prandial hypoglycemia or congenital hyperinsulinism
CA2874367C (en) 2012-05-25 2020-08-18 Camurus Ab Somatostatin receptor agonist formulations
WO2016141111A1 (en) * 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
LT3297653T (lt) 2015-05-22 2022-01-10 The Board Of Trustees Of The Leland Stanford Junior University Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
US11020484B2 (en) 2016-11-21 2021-06-01 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)
GB201816637D0 (en) 2018-10-12 2018-11-28 Heptares Therapeutics Ltd Selective somatostatin receptor agonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393050A (en) 1981-04-29 1983-07-12 The Salk Institute For Biological Studies Analogs of extended N-terminal somatostatin
US4703034A (en) * 1986-04-28 1987-10-27 Merck & Co., Inc. Novel cyclic tetrapeptide
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
WO2003045320A2 (en) 2001-11-21 2003-06-05 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Somatostatin analog and uses thereof
MY158342A (en) 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
JP2007518702A (ja) * 2003-11-25 2007-07-12 ノバルティス アクチエンゲゼルシャフト ソマトスタチン類似体処置の効力についてのバイオマーカー
GB0602639D0 (en) 2006-02-09 2006-03-22 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
SI2310042T1 (sl) 2013-03-29
US20110124555A1 (en) 2011-05-26
SMT201300030B (it) 2013-07-09
EP2310042A1 (en) 2011-04-20
JP5721624B2 (ja) 2015-05-20
JP2011527309A (ja) 2011-10-27
PL2310042T3 (pl) 2013-05-31
ES2399651T8 (es) 2020-11-18
US20160184388A1 (en) 2016-06-30
HRP20130145T1 (hr) 2013-03-31
ES2399651T3 (es) 2013-04-02
PT2310042E (pt) 2013-03-11
WO2010003939A1 (en) 2010-01-14
US9867864B2 (en) 2018-01-16
CY1113726T1 (el) 2016-06-22
US9314508B2 (en) 2016-04-19
EP2310042B1 (en) 2012-12-05

Similar Documents

Publication Publication Date Title
DK2310042T3 (da) Anvendelse af pasireotid til behandling af endogen hyperinsulinæmisk hypoglykæmi
CY2020043I1 (el) Παγιδες gdf για χρηση στη θεραπευτικη αντιμετωπιση της αναιμιας
NL300938I2 (nl) Niraparib tosylaat of niraparib tosylaat monohydraat
BRPI0817298A2 (pt) Combinações de substâncias ativas com propriedades inseticidas e acaricidas
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
DK2235002T3 (da) 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
BRPI0919438A2 (pt) mistura de poliésteres, e, uso das misturas de poliésteres
BRPI0922976A2 (pt) dispositivo e biópsia com câmaras teciduais distintas
DK2259674T3 (da) Delta-4-desaturase og anvendelse heraf i fremstillingen af flerumættedefedtsyrer
DK2114419T3 (da) Natriummetaarsenit til anvendelse i behandling af smerte og inflammation
DK2342233T3 (da) Anti-CXCR4-antistoffer og anvendelse deraf i behandling af cancer
BRPI0821352A2 (pt) Tratamento de batateiros e bananeiras com composições antifúngicas
BRPI0912292A2 (pt) composições e métodos para o uso de células no tratamento do tecido cardíaco.
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
BRPI0923015A2 (pt) enxertos ósseos com atividade de protease reduzida e métodos de seleção e uso
BRPI0817974A2 (pt) Combinações de substâncias ativas com propriedades inseticidas e acaricidas.
BRPI0922344A2 (pt) inibidores de tfpi e métodos de uso
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
DK2200600T3 (da) Neramexan til anvendelse ved behandlingen af subakut tinnitus
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
BRPI0822129A2 (pt) Inibidores de aldh-2c no tratamento de vício.
CL2008001795A1 (es) Uso de un antagonista par1 en el tratamiento de la fibrilacion atrial.
BRPI0810475A2 (pt) uso de dimiracetam no tratamento de dor crônica
DK3311810T3 (da) Anvendelse af sulcardin til behandling af atrieflimmer